Synthesis And Anticancer Studies Of

Methylene Bridged N-Heterocyclic

Carbene Silver(i) And Palladium(ii)

Complexes Derived From

Imidazol-2-Ylidenes by Hasanudin, Noorhafizah
SYNTHESIS AND ANTICANCER STUDIES OF 
METHYLENE BRIDGED N-HETEROCYCLIC 
CARBENE SILVER(I) AND PALLADIUM(II) 
COMPLEXES DERIVED FROM 
IMIDAZOL-2-YLIDENES 
 
 
 
 
 
 
 
NOORHAFIZAH BINTI HASANUDIN 
 
 
 
 
 
 
 
UNIVERSITI SAINS MALAYSIA 
2015 
SYNTHESIS AND ANTICANCER STUDIES OF METHYLENE 
BRIDGED N-HETEROCYCLIC CARBENE SILVER(I) AND 
PALLADIUM(II) COMPLEXES DERIVED FROM  
IMIDAZOL-2-YLIDENES 
 
 
 
 
by 
 
  
 
 
NOORHAFIZAH BINTI HASANUDIN 
 
 
 
 
Thesis submitted in fulfillment of the  
requirements for the degree  
of Master of Science 
 
 
 
 
 
UNIVERSITI SAINS MALAYSIA 
AUGUST 2015 
ii 
 
ACKNOWLEDGEMENT 
 
Alhamdulillah (All Praises to Allah) and I thank Him for granting me the 
persistence and the endurance to complete this thesis successfully.  
I would like to express my sincere gratitude to my supervisor Dr. Rosenani S. 
M. Anwarul Haque for the useful comments, remarks and engagement through the 
learning process of this master thesis.  
It is also my pleasure to dedicate my special thanks and appreciation to my 
sponsors IPS (USM) for giving all the financial support [fellowship: 
RU(1001/441/CIPS/AUPE001)] and PRGS grant (1001/PKIMIA/834080) 
throughout the duration of my studies. Also, I like to thank the School of Chemical 
Sciences, the School of Physics and EMAN Research and Testing Laboratory, The 
School of Pharmaceutical Sciences. 
Furthermore I would like to thank the rest of my thesis committee: Dr. 
Srivanasa, Dr. Adnan, Dr. Abbas, Mr. Mohamad, Fatimah, Zetty, Sze Yii and 
Tabintha for their encouragement, insightful comments, and hard questions. Also I 
thank my friends in USM. 
Last but not the least, I would like to thank my family members especially my 
beloved husband, Mohammad Zamri Abdul Rashid, my dearest children, 
Mohammad Izz Zarif and Mohammad Izz Ziqri, my mother, my father and my 
siblings who have provided me with their endless love, moral support, prayers and 
encouragement. May Allah always give His blessings to them in this world and the 
hereafter. Ameen. 
 
Noorhafizah Hasanudin, 2014. 
iii 
 
TABLE OF CONTENTS 
 
 Page 
Acknowledgment  ii 
Table of Contents iii 
List of Tables  vi 
List of Figures 
List of Schemes 
vii 
ix 
List of Abbreviations and Symbols 
List of Publications  
x 
xi 
Abstrak  xii 
Abstract  xiv 
CHAPTER 1 – INTRODUCTION 
 
1.1      General Background (carbene and N-Heterocyclic Carbene) 1 
1.2      Stability of NHCs 4 
1.3      NHC-Metal Complexes 5 
1.4      Syntheses of NHC Metal Complexes 
1.5      Applications of Silver(I)-NHC Complexes 
           1.5.1      Ligand Transfer Chemistry 
           1.5.2      Medicinal Chemistry 
           1.5.3      Catalysis 
1.6      Applications of Palladium(II)-NHC Complexes 
           1.6.1      Medicinal Chemistry 
           1.6.2      Catalysis 
1.7      Research Objectives 
10 
13 
13 
14 
17 
18 
18 
19 
20 
iv 
 
CHAPTER 2 - EXPERIMENTAL   
2.1      Reagents and Instruments 
2.2.    Cell Line and Culture Condition 
22 
22 
2.3      Synthesis of Reagent 
2.4      Synthesis of Methylene-Bridged Bis-imidazolium Salts 
22 
22 
           2.4.1    di(1,1’-(2-cyano)benzylimidazolium)-3,3’methylene      
dihexafluorophosphate (1) 
2.4.2    di(1,1’-(3-cyano)benzylimidazolium)-3,3’methylene 
dihexafluorophosphate (2) 
2.4.3 di(1,1’-(2-methyl)benzylimidazolium)-3,3’methylene 
dihexafluorophosphate (3) 
2.4.4 di(1,1’-(3-cyano)benzylimidazolium)-3,3’methylene 
dihexafluorophosphate (4) 
2.5     Synthesis of Dinuclear Silver(I)-DiNHC Complexes 
2.5.1    di(1,1’-(2’’-cyano)benzylimidazolium)-3,3’-methylene 
disilver(I) dihexafluorophosphate (5) 
2.5.2    di(1,1’-(3’’-cyano)benzylimidazolium)-3,3’-methylene 
disilver(I) dihexafluorophosphate (6) 
2.5.3 di(1,1’-(2’’-methyl)benzylimidazolium)-3,3’-methylene 
disilver(I) dihexafluorophosphate (7) 
2.5.4 di(1,1’-(3’’-methyl)benzylimidazolium)-3,3’-methylene 
disilver(I) dihexafluorophosphate (8)  
2.6     Synthesis of Palladium(II)-NHC Complexes 
2.6.1 di(1,1’-(3’’-methyl)benzylimidazolium)-3,3’-methylene 
palladium(II) dihexafluorophosphate (9) 
 
22 
 
23 
 
24 
 
25 
26 
 
26 
 
27 
 
28 
 
29 
30 
 
30 
v 
 
2.7  Determination of Anticancer Activity 
2.7.1  Preparation of Cell Culture 
2.7.2  MTT Assay 
CHAPTER 3 - RESULTS AND DISCUSSIONS 
3.1     The Targeted Methylene-Bridged Bis-imidazolium Salts 
3.2     Synthesis 
3.2.1 Synthesis of the Methylene-Bridged Bis-imidazolium salts  
3.2.2 Synthesis of Dinuclear Silver(I)-DiNHC Complexes 
3.2.3  Synthesis of Palladium(II)-NHC Complex 
3.3     FT-NMR Spectral Studies 
3.3.1 NMR Studies of the Methylene-Bridged Bis-imidazolium 
Salts, 1-4 
3.3.2 NMR Studies of the Silver(I)-DiNHC Complexes, 5-8 
3.3.3 NMR studies of the Pd(II)-NHC complex, 9 
3.4     Single Crystal X-Ray Diffraction Studies 
3.4.1 Single Crystal of Bis-imidazolium Salts 
3.4.2      Single Crystal of Dinuclear Silver(I)-DiNHC Complexes 
3.4.3      Single Crystal of Palladium(II)-DiNHC Complex  
3.5  In vitro Anticancer Studies against Breast Cancer (MCF-7) 
CHAPTER 4 – CONCLUSIONS                                                                           
CHAPTER 5 - RECOMMENDATIONS FOR FUTURE WORK 
REFERENCES 
APPENDICES   
31 
31 
31 
 
33 
34 
34 
35 
36 
37 
 
37 
38 
48 
51 
51 
57 
63 
66 
 
74 
76 
77 
 
vi 
 
LIST OF TABLES 
  Page 
Table 3.1 
1
H NMR (500 MHz) data for the bis-imidazolium salts 1-4 
in d6-DMSO. 
43 
Table 3.2 
13
C NMR (125 MHz) data for the bis-imidazolium salts 1-4 
in d6-DMSO.  
44 
Table 3.3 
1
H NMR (500 MHz) data for silver complexes 5-8  in d6-
DMSO. 
45 
Table 3.4 
13
C NMR (125 MHz) Data for Silver Complexes 5-8  in d6-
DMSO. 
47 
Table 3.5 
1
H and 
13
C (125 MHz) NMR data for the Pd(II)-NHC 
complex 9.  
50 
Table 3.6 Crystal data and structure refinement details for salt 1. 52 
Table 3.7 Selected bond lengths (Å) and angles (
o
) for salt 1. 53 
Table 3.8 Crystal data and structure refinement details for salt 2. 54 
Table 3.9 Selected bond lengths (Å) and angles (
o
) for salt 2. 55 
Table 3.10 Crystal data and structure refinement details for salt 4. 56 
Table 3.11 Selected bond lengths (Å) and angles (
o
) for salt 4. 57 
Table 3.12 Crystal data and structure refinement details for complex 5. 59 
Table 3.13 Selected bond lengths (Å) and angles (
o
) for complex 5. 60 
Table 3.14 Crystal data and structure refinement details for complex 7. 62 
Table 3.15 Selected bond lengths (Å) and angles (
o
) for complex 7. 62 
Table 3.16 Crystal data and structure refinement details for complex 9. 65 
Table 3.17 Selected bond lengths (Å) and angles (
o
) for complex 9. 66 
Table 3.18 IC50 Values of Ligands and Respective Complexes (1-9). 68 
 
 
vii 
 
LIST OF FIGURES 
  Page 
Figure 1.1 Ground state multiplicity of the carbene. 1 
Figure 1.2 Bonding in Fischer carbene complexes. 3 
Figure 1.3 Bonding in Schrock carbene complexes. 3 
Figure 1.4 Bonding in N-heterocylic carbene complexes. 3 
Figure 1.5 Electronic stabilization of NHC (a) Inductive effect, (b) 
Mesomeric effect, (c) Representations of resonance in 
imidazole-2-ylidenes. 
5 
Figure 1.6 Structures of chromium(III)-NHC (I), mercury(II)-NHC (II), 
the early isolated carbenes (1,3-di-1-adamantyl-imidazol-2-
ylidene) (III) and the (1,3-dimesityl-4,5-dichloroimidazol-2-
ylidene) (IV). 
7 
Figure 1.7 (a) and (b), First-generation ruthenium-based metathesis and 
(c) Second-generation ruthenium-based metathesis. 
7 
Figure 1.8 General structure of chelating alkane-bridged diNHC 
complex. 
9 
Figure 1.9 Wanzlick′s equilibrium. 12 
Figure 1.10 Platinum-based anticancer drugs. 16 
Figure 1.11 Silver(I)-NHC complexes for anticancer studies by  
Youngs et al. 
16 
Figure 1.12 The first silver(I)-NHC complexes as potential antimicrobial 
agents. 
17 
Figure 1.13 Pd(II)-NHC complexes tested for their biological properties. 19 
Figure 1.14 Pd(II)-NHC complex used as catalyst in Heck reaction. 20 
Figure 3.1 Selected region of the 
1
H NMR (500 MHz) in d6-DMSO for 
salt 1 and respective complex 5 indicating the changes in 
chemical shifts. 
40 
viii 
 
Figure 3.2 Selected region of the 
1
H NMR (500 MHz) in d6-DMSO for 
salt 3 and respective complex 7 indicating the changes in 
chemical shifts. 
41 
Figure 3.3 Selected regions of the 
13
C NMR spectra (125 MHz, d6-
DMSO) showing JC-Ag coupling observed for 5 (left) and 8 
(right). 
42 
Figure 3.4 Selected region of the 
1
H NMR(500 MHz) for silver complex 
5 and the corresponding palladium complex 9 in d6-DMSO. 
49 
Figure 3.5 Molecular structure of salt 1, showing one water molecule. 
Counter anions are omitted for clarity. 52 
Figure 3.6 Molecular structure of salt 2 with 50% probability 
displacement ellipsoids. 54 
Figure 3.7 Molecular structure of salt 4 with 50% probability 
displacement ellipsoids. 
56 
Figure 3.8 Molecular structure cationic part of complex 5 depicting the 
intermolecular Ag---Ag interaction with displacement 
ellipsoids drawn at 50% probability. 
59 
Figure 3.9 Molecular structure cationic part of complex 7 depicting the 
intermolecular Ag---Ag interaction with displacement 
ellipsoids drawn at 50% probability. 
61 
Figure 3.10 Molecular structure cationic part of palladium complex 9. See 
Appendix O with its counter anions (two hexafluorophosphate 
anions). 
64 
Figure 3.11 Marketing drugs for the treatment of breast cancer. 67 
Figure 3.12 Images of MCF-7 cells treated with standard used, bis-
imidazolium salts 1-4 after 72 h of incubation. 
69 
Figure 3.13 MTT assay results of bis-imidazolium salts 1-4 and standard 
used. 
70 
Figure 3.14 Images of MCF-7 cells treated with standard used, silver(I) 
and palladium(II)-NHC complexes 5-9 after 72 h of 
incubation. 
72 
Figure 3.15 
 
MTT assay results of silver(I) and palladium(II)-NHC 
complexes 5-9 and standard used. 
 
73 
ix 
 
LIST OF SCHEMES 
  Page 
Scheme 1.1 Synthesis of first Fischer carbene. 2 
Scheme 1.2 Synthesis of Schrock carbene. 3 
Scheme 1.3 Synthesis of chelated-biscarbene precursor. 9 
Scheme 1.4 Synthesis of palladium-diNHC complexes. 9 
Scheme 1.5 Synthesis of biscarbene rhodium-NHC complexes that 
shown potential to be used in radiation therapy.  
10 
Scheme 1.6 (a) Syntheses of Ag(I)-NHC complexes using Ag2O act 
as internal base,(b) Synthesis of Ir(II)-NHC complex 
using NaOAc as an external base and IrCl(COD)2 as a 
metal source. 
11 
Scheme 1.7 Transmetallation reactions leading to palladium- and 
rhodium-NHC complexes. 
12 
Scheme 1.8 The first NHC transfer reaction from Ag(I)-NHC 
complex to Pd(II) and Au(I).  
14 
Scheme 3.1 Synthesis of di(1H-imidazol-1-yl)methane. 35 
Scheme 3.2 Typical reaction for the synthesis of bis-imidazolium 
salts 1-4. 
37 
Scheme 3.3 Synthesis of silver(I)-NHC complex 5.  36 
Scheme 3.4 Synthesis of silver(I)-NHC complex 7. 36 
Scheme 3.5 Synthesis of palladium(II)-NHC complex 9. 37 
 
 
 
 
 
 
x 
 
LIST OF ABBREVIATIONS AND SYMBOLS 
 
Å  Angstrom, 1 × 10 
−10
 m 
°C  Degrees Celsius 
FT-NMR Fourier transform nuclear magnetic resonance 
13
C-NMR  Carbon-13 nuclear magnetic resonance 
1
H-NMR  Proton nuclear magnetic resonance 
CHN Carbon, hydrogen and nitrogen 
δ  Chemical shift in ppm 
d  Doublet 
t Triplet 
m Multiplet 
DMSO  Dimethylsulfoxide 
h  Hours 
Hz  Hertz 
J  Coupling constant 
MHz  Megahertz 
mmol  Millimoles 
mol  Moles 
RT  Room temperature 
M  Molar 
NHC  N-heterocyclic carbene 
μM Micromolar 
MCF-7 Human breast cancer 
Et Ethyl 
xi 
 
LIST OF PUBLICATIONS 
Haque, R.A., Budagumpi, S., Zetty Zulikha, H., Hasanudin, N., Khadeer Ahamed, 
M.B. and Abdul Majid, A.M.S. (2014). Silver(I)-N-heterocyclic carbene 
complexes of nitrile-functionalized imidazol-2-ylidene ligands as anticancer 
agents. Inorganic Chemistry Communications, 44: 128-133. 
Haque, R.A., Hasanudin, N., Iqbal, M.A., Ahmed, A.,Hashim, S., Abdul Majid, A. 
and  Ahamed, M.B.K. (2013). Synthesis, crystal structures, in vitro 
anticancer, and in vivo acute oral toxicity studies of bis-
imidazolium/benzimidazolium salts and respective dinuclear Ag(I)-N-
heterocyclic carbene complexes. Journal of Coordination Chemistry, 66(18): 
3211-3228. 
Haque, R. A., Iqbal, M. A., Budagumpi, S., Khadeer Ahamed, M.B., Abdul Majid, 
A.M.S. and Hasanudin, N. (2013). Binuclear meta-xylyl-linked Ag(I)-N-
heterocyclic carbene complexes of N-alkyl/aryl-alkyl-substituted bis-
benzimidazolium salts: Synthesis, crystal structures and in vitro anticancer 
studies. Applied Organometallic Chemistry. 27(4): 214-223. 
Haque, R. A., Iqbal, M. A., Hasanudin, N. and Nasri, S. F. (2010). Synthesis and 
characterization of methylated and benzylated imidazole linked new 
carboxamides. Science International-Lahore, 22: 275-279. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xii 
 
SINTESIS DAN KAJIAN ANTIKANSER KOMPLEKS PERAK(I) DAN 
PALLADIUM(II) TITIAN METIL N-HETEROSIKLIK KARBENA 
TERBITAN IMIDAZOL-2-ILIDENA 
 
 
ABSTRAK 
 
Tesis ini menerangkan sintesis, pencirian (
1
H, 
13
C NMR, CHN, takat lebur) dan 
aktiviti kanser bagi titian metil garam bis-imidazolium (1-4) dan kompleks perak(I)-
N-heterosiklik karbena (NHC). Kesemua garam bis-imidazolium ditindak balas 
dengan punca logam bes, perak oksida, melalui tindak balas pengkompleksan ringkas 
untuk menghasilkan empat kompleks perak baru (5-8) dengan hasil yang sangat 
memuaskan (61-71%). Penggunaan kompleks perak(I)-NHC sebagai reagen 
pemindahan karbena kepada kompleks palladium(II)-NHC (9) telah berjaya 
disintesis. Kesemua sebatian yang terhasil telah dicirikan melalui teknik spektal dan 
analitikal seperti NMR spektroskopi (
1
H dan 
13
C) dan analisis unsur. Struktur 
molekul untuk tiga garam bis-imidazolium, dua kompleks perak dan satu kompleks 
palladium telah dikenalpasti melalui teknik pembelauan sinaran-X kristal tunggal. 
Kajian struktur sinar-X untuk kompleks perak mengesahkan bahawa struktur 
kompleks perak terdiri daripada dua kation perak di apit oleh dua unit ligan. 
Kesemua garam, kompleks perak dan palladium adalah bukan bersifat hidroskopik 
dan menunjukkan kestabilan terhadap udara, lembapan dan haba. Aktiviti antikanser 
untuk semua garam bis-imidazolium, kompleks perak dan kompleks palladium telah 
diuji melawan sel kanser payudara manusia (MCF-7), dengan menggunakan 
tamoxifen sebagai ubat piawai (IC50 = 2.4 µM). Garam-garam bis-imidazolium 
menunjukkan tiada aktiviti untuk garisan MCF-7, kecuali garam 4; menunjukkan 
aktiviti sederhana baik (IC50 = 30 µM). Sementara itu, kesemua kompleks perak dan 
xiii 
 
palladium memaparkan aktiviti antikanser yang signifikan dengan nilai IC50 diantara 
0.5-6.2 μM terhadap garisan sel yang diuji. 
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SYNTHESIS AND ANTICANCER STUDIES OF METHYLENE BRIDGED 
N-HETEROCYCLIC CARBENE SILVER(I) AND PALLADIUM(II) 
COMPLEXES DERIVED FROM IMIDAZOL-2-YLIDENES 
 
ABSTRACT 
 
This thesis presents the synthesis, characterization (
1
H, 
13
C NMR, CHN, melting 
point) and anticancer activity of new methylene-bridged bis-imidazolium salts (1-4) 
and their respective silver(I)-N-heterocylic carbene (NHC) complexes. All bis-
imidazolium salts were treated with a basic metal source, silver oxide, via a simple 
complexation reaction to afford four silver complexes (5-8) in exceptionally good 
yields (61-71%). The use of silver(I)-NHC complex as NHC transfer reagents was 
shown to be successful to synthesize palladium(II)-NHC complex (9). All isolated 
compounds were characterized by spectral and analytical techniques viz., NMR (
1
H 
and 
13
C) spectroscopy and elemental analysis. Molecular structure of three 
imidazolium salts, two silver complexes and one palladium complex were 
established through the single crystal X-ray diffraction technique. X-ray structural 
studies for silver complexes established that the structures of each silver complex are 
comprised of two silver cations sandwiched by two NHC units. The structural 
analysis of palladium complex 9 show that it is a mononuclear Pd(II) complex, 
chelated by two units of ligands. All the prepared salts, silver complexes and 
palladium complexes were non-hygroscopic and showed stability towards air, 
moisture and heat. The in vitro anticancer activity of all bis-imidazolium salts, silver 
complexes and palladium complexes were investigated against the human breast 
cancer (MCF-7) cell line, using tamoxifen as standard drug (IC50 = 2.4 µM).  The 
bis-imidazolium salts demonstrated no activity for MCF-7 cell line, except salt 4; 
showing moderate activity (IC50 = 30 µM). Whereas, all the silver and palladium 
xv 
 
complexes displayed significant activity with IC50 values in the range 0.5-6.2 μM 
against tested cell line.  
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CHAPTER ONE 
INTRODUCTION  
1.1 General background (carbene and N-heterocylic carbene) 
A carbene is defined as an organic molecule containing a divalent carbon atom 
with two non-bonding electrons and has general formula ׃CR2. Most of the carbenes 
are very reactive, unstable and easier said than done to isolate. Carbenes can be 
classified as either in singlet state or triplet state depending on their electronic 
configurations. Singlet carbenes have two electrons (antiparallel spin-paired) that are 
not involved in bonding, whereas in the triplet carbenes, two electrons reside in two 
different orbitals with parallel spins as illustrated in Figure 1.1 (Bourissou et al., 
2000). 
Figure 1.1: Ground state multiplicity of the carbene.  
 In 1964, Fischer and Maasböl synthesized the first stable Fischer carbene 
complex with tungsten (Scheme 1.1). Fischer carbenes are considered as singlet 
carbenes which donate their electron pair as σ mode from sp2 hybrid orbital and use 
the p-orbital to accept back donation from the metal in a π mode (Figure 1.2) 
(Fischer and Maasböl, 1964). 
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 One decade after Fischer discovery, the second type of carbene was 
discovered by Schröck in 1974. The treatment of Ta(CH2CMe3)3Cl2 with two 
equivalents of Li(CH2CMe3) resulted in the first stable Schröck carbene complex 
(CH2CMe3)3Ta(CHCMe3) (Scheme 1.2). Schröck carbenes are considered as triplet 
and nucleophilic carbenes. This type of carbene is found in early transition metal 
complexes with higher oxidation states, such as Ta(V), Ti(IV) and W(V) (Schröck, 
1974). These carbenes tend to form two covalent bonds with the metal. The bonding 
between metal and carbene takes place by interaction between two unpaired electrons 
on the carbene and the metal as depicted in Figure 1.3.  
 In contrast to Fisher and Schröck carbenes, N-heterocyclic carbenes (NHCs) 
are singlet neutral carbenes and are generally prepared by deprotonation of azolium 
salts, using a strong base such as potassium hydroxide or sodium hydroxide. 
Deprotonation leaves electron pair on the carbon thus producing carbene. This 
electron pair occupies a σ orbital, leaving an empty p-orbital that remains available to 
share the electron density of the lone pairs of the nitrogen atoms on both sides of it. 
The lone pair of the carbene is donated to the metal in order to form Metal−Carbon 
bond. The bonding in NHC complex is depicted in Figure 1.4. 
 
 
 
 
Scheme 1.1: Synthesis of first Fischer carbene. 
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Figure 1.2: Bonding in Fischer carbene complexes. 
 
 
 
 
 
 
 
 
Scheme 1.2: Synthesis of Schröck carbene. 
    
 
 
Figure 1.3: Bonding in Schröck carbene complexes. 
 
 
 
 
Figure 1.4: Bonding in N-heterocylic carbene complexes. 
 
 π backbonding from 
metal to the carbene 
& direct σ donation 
to the metal center 
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1.2 Stability of NHCs 
Diaminocarbenes, or NHCs, are unique class of carbene family which has 
attracted much attention of organometallic chemists. As ligands, NHCs are very good 
σ donors and can coordinate with metal center in a wide variety of oxidation states 
(low and high oxidation states) (Herrmann, 2002). Conversely to Fisher and Schröck 
type carbene, NHCs are extremely air-stable and inert ligands when coordinated to a 
metal center. The stability of NHCs are mainly resulted by electronic effects 
(Arduengo et al., 1993). This stabilization is due to the ′push-pull′ mechanism. In 
brief, the electronegative nitrogens inductively stabilize by pulling the electron 
density away from the carbene center (σ stabilization), while the energy of the vacant 
pπ orbitals increases by interaction with the symmetric combination of the two π 
electrons from both nitrogen atoms (π stabilization) (Figure 1.5) (Bourissou et al., 
2000).  
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Figure 1.5: Electronic stabilization of NHC (a) Inductive effect, (b) Mesomeric 
effect, (c) Representations of resonance in imidazole-2-ylidenes. 
 
1.3 NHC metal complexes 
 In 1968, the use of NHCs as ligands for transition  metal-NHC complexes 
was first time explored by Öfele and Wanzlick who prepared Cr(III)- (I) and Hg-(II)-
NHC (II), respectively (Figure 1.6) (Wanzlick & Schönherr, 1968). After that, NHCs 
have been extensively explored and used as catalysts in a number of reactions, such 
as transfer hydrogenation, Heck and Suzuki coupling, aryl amination, and olefin 
polymerization. Furthermore, metal-NHC complexes have received much attention 
for their catalytic ability due to their ability to stabilize metal centers in variety of 
(a) (b) 
(c) 
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oxidation states, which play important role in homogeneous catalysis (Herrmann et 
al., 1998; Herrmann et al., 2002, Scholl et al., 1999, Sanford et al., 2001). Although 
many metal complexes of carbenes were synthesized much earlier but no free 
carbenes were reported as isolable in any of these cases. Later, in 1991 Arduengo 
and co-workers made the breakthrough of isolating the first crystalline carbenes, 1,3-
di-1-adamantyl-imidazol-2-ylidene (III), which subsist as a solid but it is air and 
moisture-sensitive (Arduengo et al., 1991). Few years after, the same group was able 
to synthesize the first air-stable carbene, 1,3-dimesityl-4,5-dichloroimidazol-2-
ylidene, (IV) (Figure 1.6) (Arduengo et al., 1997).  The popularity and interest in 
metal-complexes of NHCs increased among researchers after various reports 
showing their tendency in catalytic activity (Scholl et al., 1999). 
 In the early 1990s, striking similarities between NHCs and phosphine ligands, 
in terms of ligand properties and metal coordination chemistry, were recognized by 
Herrmann and co-workers (Herrmann et al., 1993). Like phosphines, NHCs ligands 
are excellent σ donors and having both steric and electronic tunability which make 
them capable to promote a wide variety of catalytic reactions. Initially, Grubb and 
co-workers synthesized the ruthenium-based catalyst, (PCy3)2(Cl)2-Ru=CHPh (a) 
and (PPh3)2(Cl)2-Ru=CHPh (b), that swiftly gained popularity due to their stability 
and catalytical activity in olefin metathesis reactions. Subsequently, the same group 
replaced a phosphine by an NHC ligand to develop “second generation of Grubbs 
catalyst”. This NHC-Ru complex (c) was synthesized and used to improve the 
performance of Grubb metathesis reaction (Figure 1.7) (Sanford et al., 2001; Trnka 
et al., 2003). 
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Figure 1.6: Structures of Cr(III)-NHC (I), Hg(II)-NHC (II), the early isolated free 
carbenes (1,3-di-1-adamantyl-imidazol-2-ylidene) (III) and the (1,3-dimesityl-4,5-
dichloroimidazol-2-ylidene) (IV). 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: (a) and (b), First-generation ruthenium-based metathesis and (c) Second-
generation ruthenium-based metathesis. 
  
 Miscellaneous of NHC structures has been explored as their applications have 
grown. One of which is biscarbenes system which have been further explored in the 
current research. BisNHCs offer entropic stability to their complexes and this type of 
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ligands, in general, has established to be very useful in organometallic catalysis. The 
first strategy to synthesize biscarbene ligands are normally by direct reaction 
between N-alkyl or –arylimidazole with one of the desired alkyl dihalide (Albrecht et 
al., 2002; Köcher & Herrmann, 1997). Figure 1.8 illustrates general structure of 
bidentate chelating alkane-bridged diNHC complex and this type of complex can be 
simply modified by either varying the N-subsituents or the length of the alkyl chain 
between the two imidazoylidene units.  
 The second strategy to obtain biscarbene precursors was shown in Scheme 
1.3. The nucleophilic substitution reaction of the dibromomethyl compound with 2 
imidazole units was followed by quaternization process with methyl iodide, give the 
desired bis-imidazolium salt. This bis-imidazolium salt was further used for 
metallation with palladium and nickel (Clyne et al., 2000). In 1995, Fehlhammer et 
al. reported the first example of chelating diNHC-palladium complex (Scheme 1.4) 
(Fehlhammer et al., 1995). Subsequently, Herrmann and coworkers synthesized the 
bidentate free NHC in high yield and this free carbene was further used to synthesize 
the bis-NHC complexes of Ru(II), Os(II), Rh(I), Ir(I) and Pd(II) (Herrmann et al., 
1996). Further work on catalytic study has shown that diNHC complexes are 
catalytically active for a wide range of reactions such as Kumada-Corriu and Suzuki 
Coupling reactions. Because of their common applications in catalytic field, the 
chemistry of poly-NHC complexes is in continuous development. Several palladium-
NHC complexes with cis-chelating diNHC ligands have been shown to efficiently 
catalyze cross coupling reactions (Chiu et al., 2005; Schaub & Radius, 2005; Xi et 
al., 2007). 
 Another interesting application of chelating biscarbene complexes was 
reported by Quezada and co-workers. They found that Rh(II)-complexes obtained via 
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transmetallation of Ag(I)-carbene may have applications in radiation therapy 
(Scheme 1.5) (Quezada et al., 2004). Later, in 2005, Garrison and co-workers believe 
that chelating-NHC ligands may have potential to be used as metal chelators in the 
synthesis of radiopharmaceuticals (Garrison et al., 2005). 
 
 
 
Figure 1.8: General structure of alkane-bridged diNHC complex. 
 
  
 
 
 
Scheme 1.3: Synthesis of biscarbene precursor. 
 
 
 
 
 
 
 
 
Scheme 1.4: Synthesis of Pd-diNHC complexes. 
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Scheme 1.5: Synthesis of biscarbene Rh-NHC complexes that shown potential to be 
used in radiation therapy (Quezada et al., 2004). 
 
1.4 Syntheses of NHC metal complexes 
Nowadays, there are numerous ways of generating NHC metal complexes. 
The most widely used method is in situ deprotonation of azolium salts in the 
presence of suitable metal ion. The basic ligands (OR
- 
or OAc
-
) present in the metal 
precursor can act as an internal base (Baker et al., 2001). One of the most commonly 
used bases, for deprotonation which also acts as a metal source, is Ag2O (Catalano & 
Etogo, 2007; Paulose et al., 2008; Simons et al., 2003). The use of external bases 
(lithium or potassium tert-butoxide or sodium acetate) can be added for in situ 
deprotonation (Scheme 1.6) (Baker et al., 2006; Han et al., 2008). By using this 
strategy, the isolation of the free NHC is not necessary. This strategy is also suitable 
to perform one-pot synthesis, thus making this method popular in preparing NHC 
complexes. 
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Scheme 1.6: (a) Syntheses of Ag(I)-NHC complexes using Ag2O act as internal 
base,(b) Synthesis of Ir(II)-NHC complex using NaOAc as an external base and 
IrCl(COD)2 as a metal source. 
 
Apart from in situ deprotonation method, the isolation of the free carbene is 
also commonly used. This method necessitates deprotonation of azolium salt using 
strong base such as NaH and t-BuOk or dimsyl anions to produce the free carbene, 
(Arduengo et al., 1991) and this carbene can be isolated or directly used without 
isolation. The main advantage by using this method is the large diversity of metal 
precursors that can be used without special requirements regarding the ligand sphere 
and the oxidation state of metal center (Weskamp et al., 2000). However, this 
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method can pose problems such as ligand decomposition and dimerisation of the free 
carbene by attaining Wanzlick equilibrium (Figure 1.9) (Böhm & Herrmann, 2000). 
Another method is the carbene transfer method (transmetallation) by using Ag-NHC 
complexes. This method was introduced by Lin and co-workers in 1998. The lability 
of Ag-carbene bond allowed silver to be replaced by another metal center to form 
new metal-NHC complexes. As of today, many metal-carbene complexes such as Pd-
, Rh- (Scheme 1.7) (Simons et al., 2003), Ru-NHC complexes are prepared by using 
this route (Trnka et al., 2003). 
 
 
 
 
Figure 1.9: Wanzlick′s equilibrium. 
 
 
 
 
 
 
 
 
 
Scheme 1.7: Transmetallation reactions leading to Pd- and Rh-NHC complexes. 
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1.5 Applications of silver(I)-NHC complexes  
1.5.1 Ligand transfer chemistry 
 The metal-NHC chemistry, especially Ag(I)-NHCs, has received a great deal 
of attention from many researchers. The first use of Ag(I)-NHCs in transmetallation 
was introduced by Wang and Lin (Wang and Lin, 1998) (Scheme 1.8). The growing 
interest of Ag(I)-NHCs due to their straightforward method, stability of NHCs, 
fascinating structural diversity and also most prominently excellent as transfer agents 
(Barnard et al., 2004; Lin & Vasam, 2004, 2007). In transmetallation route, the NHC 
salt is reacted first with Ag2O to give the Ag(I)-NHC complex. Further reaction of 
Ag(I)-NHC complexes with the targeted metal source affords the metal-NHC 
complex by transferring NHC ligand from silver center to the other metal centers 
(Garrison et al., 2005). Recently, Ag(I)-NHC complexes also have been reported as 
convenient precursors to prepare a variety of  metal-NHC complexes such as Cu(I) 
(Liu et al., 2013), Pt(II) and Ni(II), (Chen et al., 2011), Pd(II), Ru(II) and Rh(I) 
(Lang et al., 2013). 
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Scheme 1.8: The first NHC transfer reaction from Ag(I)-NHC complex to Pd(II) and 
Au(I).  
 
1.5.2 Medicinal chemistry 
 Aside from their place in ligand transfer chemistry, silver compounds also 
have prominent place in bioorganometallic chemistry. In the history of medicinal 
chemistry, silver has been extensively used throughout for a variety of medical 
purposes such as in cancer treatment. Today, cancer treatment has been a major focus 
on research and development in academia and pharmaceutical fields. Cancer is often 
referred to as “the silent killer.” At the onset of cancer, cancer cells are difficult to 
identify; by the time they have been detected, not much can be done to cure the 
patient. Cancer is a broad term for a class of diseases in which abnormal cells divide 
without control and invade other normal cells in the body.  
 The first historical example of metal-based drugs that used in cancer 
treatment is cisplatin. Cisplatin is commonly used for the treatment of a variety of 
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cancers. The metal-based drug show 70-90% cure rate for testicular cancer and is 
effective against brain, ovarian, bladder and breast cancer when combined with other 
drugs (Marzano et al., 2002). Later on, various cisplatin analogous compounds such 
as carboplatin, oxaliplatin, nedaplatin and lobaplatin have been approved for current 
tumor therapy (Figure 1.10) (Wheate et al., 2010). However, the use of platinum-
based anticancer drugs in clinical applications is restricted as most of the tumors 
have resistance against the mentioned drugs and their side effects can be severe. Due 
to this situation, the quest for selective anti-invasive agents with low toxicity for 
cancer treatment is urgently required. Where silver and gold becomes the suitable 
canditates due to their lower toxicity compared to platinum. 
 In 2008, Youngs and co-workers have reported anticancer properties of 
Ag(I)-NHC complexes (Figure 1.11) against the human derived cancer cell lines, 
OVCAR-3 (ovarian), MB157 (breast), and Hela (cervical) (Medvetz et al., 2008). 
Later, Tacke group have tested some of symmetrical and unsymmetrical Ag(I)-NHC 
complexes against renal cancer (Caki-1) cell line and the results are consistent with 
those reported by Youngs group (Patil et al., 2010, 2011a, 2011b). Recently, 
Gautiers and co-workers have investigated the anticancer potential of Ag(I)-NHC 
complexes against several cancerous cell lines (KB: oral carninoma, HL60: 
promyelocytic leukaemia, HL60R: resistant HL60, MCF-7: breast cancer, MCF-7R: 
resistant MCF-7, T47D: breast cancer (Gautier & Cisnetti, 2012). 
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Figure 1.10: Platinum-based anticancer drugs. 
  
 
 
 
 
 
 
 
 
 
Figure 1.11: Ag(I)-NHC complexes for anticancer studies by Youngs et al. 
  
 Silver commonly used as antimicrobial for more than hundred years and it 
was targeted for water purification, wound care antiseptics and infections (Klasen, 
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2000; Russel, 1994; Silver et al., 2006). Although the use of silver as antibiotic agent 
had proven effective for many years, its popularity declined with the discovery of 
penicillin and other antibiotics (Lansdown, 2004). In few years back, Ag(I)-NHC 
complexes have gained a significant amount of interest in medicinal research. The 
first use of Ag(I)-NHC complexes as antimicrobial agents was reported by Youngs 
and co-workers in 2004 (Figure 1.12). These Ag(I)-NHC complexes showed better 
antimicrobial activity than AgNO3 against the microorganisms; Escherichia coli, 
Staphylococcus aureus and Pseudomonas aeruginosa (Youngs et al., 2004). Today, 
many of articles dealing with Ag(I)-NHC complexes shown a great potential as 
anticancer and antimicrobial agents (Budagumpi et al., 2012; Patil et al., 2011a).    
 
 
 
Figure 1.12: The first Ag(I)-NHC complexes as potential antimicrobial agents. 
 
1.5.3 Catalysis 
 Since the last two decades, Ag(I)-NHC complexes have been explored for 
their catalytic potential. Ramírez and co-workers reported the use of Ag(I)-NHC 
complexes as catalyst for diboration reactions with terminal and internal alkenes 
(Ramírez et al., 2005). Futhermore, Ag(I)-NHC complexes were reported to be used 
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as catalysts for the ring-opening polymerisation of lactide (Sentman et al., 2005). 
Nevertheless, compared to the other metal-NHC complexes such as palladium, 
ruthenium, nickel, rhodium and iridium very few studies have been reported for 
Ag(I)-NHC complexes and this indicates Ag(I)-NHC complexes  are not very 
stunning in this field (Herrmann, 2002).  
 
1.6 Applications of palladium(II)-NHC complexes  
1.6.1 Medicinal chemistry 
 Pd(II)-NHC complexes are not very prominent in medicinal field but still 
have been explored as a potential alternative to treat several cancers unresponsive to 
current cancer treatments. In 2007, Ray and co-workers synthesize and studied the 
efficiency of Pd(II)-NHC complexes against HCT 116 (colon adenocarcinoma), 
HeLa (cervical cancer) and MCF-7 (breast cancer) and the results were found to be 
considerably stronger than cisplatin (Ray et al., 2007). Recently, Pd(II)-NHC 
complexes were tested against Escherichia coli and  Staphylococcus aureus bacteria 
and displayed comparable antimicrobial activities at the MIC level. These Pd(II)-
NHC complexes were also investigated on their anticancer activities against HCT 
116 cancer cell lines and one of Pd(II)-NHC complexes showed significant 
anticancer activity (Haque et al., 2013). Figure 1.13 shows a few of Pd(II)-NHC 
complexes tested for their biological properties. 
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Figure 1.13: Pd(II)-NHC complexes tested for their biological properties. 
 
1.6.2 Catalysis 
 Over the past two decades, Pd(II)-NHC complexes were first reported by 
Hermann and co-workers as catalyst in the Heck coupling of aryl halides with n-
butyl acrylate to afford high yield product. Figure 1.14 shows the Pd(II)-NHC 
complex that was used in Heck reaction and this complex exhibited high thermal 
stability of the Pd-Ccarbene bonds of the catalyst in solution (Herrmann et al., 1998; 
Herrmann et al., 1995). Later on, the interest of Pd(II)-NHC complexes in catalysis 
fields have grown especially in cross-coupling chemistry. Numerous of Pd(II)-NHC 
complexes have been applied as catalysts in various organic syntheses due to their 
stability towards air and moisture, low-to-moderate cost and the availability of 
palladium in the stable and variable oxidation states. Specifically, diNHC of Pd(II)-
complexes have shown extreme stability in the presence of heat and moisture leading 
to notable catalytic properties (Budagumpi et al., 2012). 
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Figure 1.14: Pd(II)-NHC complex used as catalyst in Heck reaction. 
 
1.7  Research objectives 
 The available literature shows that the Ag(I)-NHC complexes 
reported as anticancer agents mostly are mono-nuclear type. However, there is very 
less published work related to the anticancer properties of metal-NHC complexes to 
date. With this background, the current research embarked on the following 
objectives: 
 (i) To synthesize novel bis-imidazolium salts and their respective Ag(I)-
NHC complexes. 
 (ii) To use selected Ag(I)-NHC complex as transfer agent in order to 
synthesize Pd(II)-NHC complex. 
 (iii) To characterize all the synthesized compounds using different spectral 
  and analytical methods.  
(iv) To evaluate the anticancer activity of bis-imidazolium salts, Ag(I)- 
and Pd(II)-NHC complex against breast cancer cell line MCF-7. 
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CHAPTER 2 
 
EXPERIMENTAL 
 
2.1     Reagents and instruments 
Imidazole (Merck, 99.0%), 2-bromomethylbenzonitrile (Merck, for 
synthesis), 3-bromomethylbenzonitrile (Merck, for synthesis), 2-
methylbenzylbromide (Sigma-Aldrich, 96.0%), 3-methylbenzylbromide (Sigma-
Aldrich, 96.0%), potassium hexafluorophosphate (Across Organics, 99.0%), 
potassium hydroxide pallets (R&M chemicals, 85%), dichloromethane (QReC, 
99.8%), silver(I) oxide (Merck, 99.0%), dichloro(1,5-cyclooctadiene)palladium(II) 
(Sigma-Aldrich), and celite (Merck, size: 0.02-0.1 nm) were obtained from 
commercial sources and used as received. Di(1H-imidazol-1-yl)methane was 
prepared according to the literature method with slight modifications (Panzner, 
2006). 
All the reactions were carried out under aerobic conditions. 
1
H and 
13
C NMR 
spectra were recorded on a Bruker Avance 500 MHz spectrometer at ambient 
temperature from solutions in d6-DMSO or d3-CD3CN using TMS as an internal 
reference. Data were represented as follow: chemical shift (integration, spin 
multiplicity (s = singlet, d = doublet, t = triplet, q= quartet, m = multiplet), coupling 
constant in Hertz (Hz), assignment). Elemental analyses (CHN) were performed on 
Perkin Elmer series II, 2400 microanalyzer. X-ray diffraction data were recorded 
using a Bruker SMART APEX2 CCD area-detector diffractometer and were 
performed by X-ray Crystallography Unit, The School of Physics, USM. The melting 
points were assessed by using a Stuart Scientific SMP-1 (UK) instrument. 
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2.2 Cell line and culture condition 
  Breast cancer (MCF-7) cell line was purchased from American type culture 
collection (Rockvill, MD, USA). MCF-7 cell line is derived from pleural metastasis 
of ductal human breast carcinoma and was grown in DMEM medium. The growth 
media was supplemented with 10% HIFBS and 1% PS. Cells were cultured in 5% 
CO2- humidified atmosphere at 37 
o
C. 
 
2.3     Synthesis of reagent 
 Synthesis of di(1H-imidazol-1-yl)methane was prepared according to the 
literature method (Panzner, 2006) with slight modifications (As has been described 
in page 34).  
 
di(1H-imidazol-1-yl)methane 
 
2.4     Synthesis of methylene-bridged bis-imidazolium salts  
 For salt 1-4, in metathesis reaction, the ratios of KPF6 were used at least more 
than 0.5 moles excess from bromide salts. 
2.4.1 di(1,1′-(2-cyano)benzylimidazolium)-3,3′methylene dihexafluorophosphate 
(1) 
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2-(Bromomethyl)-benzonitrile (2.65 g, 0.0136 mole) was added to a stirred 
solution of di(1H-imidazol-1-yl)methane) (1.0 g, 0.0068 mole) in 1,4-dioxane (100 
mL). The mixture was refluxed at 100 °C for 24 h. The solution was evaporated in 
vacuo to yield brownish mother-liquor (92.6%). For characterization purpose the 
hexafluorophosphate salt of the compound was used whereas for further synthesis 
halide salt was used. So obtained bromide salt (2.5g, 0.0046 mole) was directly 
converted to its hexafluorophosphate salt by metathesis reaction using KPF6 (1.27 g, 
0.0069 mole) in 50 mL of methanol and stirred for 3 h. The white precipitates 
obtained were collected and recrystallized using acetonitrile to yield colorless 
crystals. Yield:  2.0 g (66.7%), m.p. = 200-201 °C, 
1
H NMR (500 MHz, d6-DMSO): 
δ 5.74 (4H, s, 2 × Nimid-CH2-Ar), 6.67 (2H, s, Nimid-CH2-Nimid), 7.52 (2H, d, J = 7.5 
Hz, Ar-H), 7.65 (2H, m, Ar-H), 7.81 (2H, m, Ar-H), 7.89 (2H, t, 2 × imidazolium 
H5′), 7.98 (2H, d, J = 7.5 Hz, Ar-H), 8.05 (2H, t, 2 × imidazolium H4′), 9.52 (2H, s, 
2 × imidazolium H2′); 13C{1H} NMR (125 MHz, d6-DMSO); 50.7 (2 × Nimid-C-Ar, 
benzylic), 58.5 (2 × Nimid-C-Nimid, methylene), 122.8, 129.6 (imidazolium C5′ and 
C4′), 111.1 (C-CN), 116.7 (CN), 129.6, 129. 9, 133.7, 134.0, 136.8 (Ar-C), 138.4 
(NCN). Anal. Calc for C23H22N6F12P2.H2O: C, 41.12; H, 3.22; N, 12.21%. Found: C, 
40.74, H, 2.50, N, 12.19%.  
 
2.4.2 di(1,1′-(3-cyano)benzylimidazolium)-3,3′methylene dihexafluorophosphate 
(2) 
 
 
3-(Bromomethyl)-benzonitrile (2.37 g, 0.012 mole) was added to a stirred 
solution of di(1H-imidazol-1-yl)methane (0.9 g, 0.0061 mole) in dioxane (100 mL). 
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The mixture was refluxed at 100 °C for 24 h. The solution was evaporated in vacuo 
to yield white precipitate (77.6%). So obtained bromide salt (1.56 g, 0.0029 mole) 
was directly converted to its hexafluorophosphate salt by metathesis reaction using 
KPF6 (1.06 g, 0.0058 mole) in 50 mL of methanol and stirred for 3 h. The white 
precipitates obtained were collected and then recrystallized using acetonitrile to yield 
colorless crystals. Yield: 1.30 g (67.3%), m.p. = 192-193 °C, 
1
H NMR (500 MHz, d6-
DMSO): δ 5.55 (4H, s, 2 × Nimid-CH2-Ar), 6.59 (2H, s, Nimid-CH2-Nimid), 7.66 (2H, t, 
2 × imidazolium H5′), 7.80 (2H, t, 2 × imidazolium H4′), 7.89, 7.90, 7.92 (Ar-H),  
7.99 (2H, s, Ar-H), 9.51 (2H, s, 2 × imidazolium H2′); 13C{1H} NMR (125 MHz, d6-
DMSO); 51.4 (2 × Nimid-C-Ar, benzylic), 58.5 (2 × Nimid-C-Nimid, methylene), 122.7, 
123.2 (imidazolium C5′ and C4′), 111.9 (C-CN), 118.3(C-N), 130.2, 132.1, 1.32.6, 
133.5, 135.6 (Ar-C), 138.1 (NCN). Anal. Calc for C23H22N6F12P2: C, 41.21; H, 3.01; 
N, 12.54%. Found: C, 40.96, H, 2.36, N, 12.20%.  
 
2.4.3 di(1,1′-(2-methyl)benzylimidazolium)-3,3′methylene dihexafluorophosphate 
(3) 
 
 
2-Methylbenzylbromide (2.50 g, 0.0135 mole) was added to a stirred solution 
of di(1H-imidazol-1-yl)methane (1.0 g, 0.0068 mole) in dioxane (60 mL). The 
mixture was refluxed at 100 °C for 24 h. The solution was evaporated in vacuo to 
yield white precipitates (77.7%). So obtained bromide salt (1.0 g, 0.0019 mole) was 
directly converted to its hexafluorophosphate salt by metathesis reaction using KPF6 
(0.8 g, 0.0044 mole) in 50 mL of methanol and stirred for 3 h. The white precipitates 
